Norditropin Nordiflex (Somatropin)

Somatropin, the active ingredient in Norditropin Nordiflex, is a growth hormone presented as a recombinant protein for subcutaneous use. It is indicated for treating growth hormone deficiency and related growth disorders in children and adults. GNH USA supplies Norditropin Nordiflex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Norditropin Nordiflex is a recombinant growth hormone used to address conditions characterized by insufficient endogenous growth hormone activity. - Growth hormone deficiency in children: stimulates linear growth and improves body composition. - Turner syndrome: supports height increase and metabolic health. - Prader‑Willi syndrome: enhances growth velocity and body composition. - Chronic renal insufficiency‑associated growth failure: promotes growth despite renal disease. - Short stature due to idiopathic causes: facilitates height gain. - Adult growth hormone deficiency: improves muscle mass, bone density and quality of life.

Norditropin Nordiflex may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain or erythema - Headache - Joint stiffness or arthralgia - Edema of the extremities - Hyperglycemia or impaired glucose tolerance

Serious or Rare Side Effects: - Intracranial hypertension - Acute pancreatitis - Severe allergic reactions (anaphylaxis, urticaria) - Development of anti‑somatropin antibodies - Cardiomyopathy or cardiac dysfunction

Before initiating therapy, clinicians should evaluate relevant medical history and monitor ongoing treatment. - Monitor glucose metabolism: assess fasting glucose and HbA1c periodically. - Screen for intracranial hypertension: watch for headaches, visual changes, or papilledema. - Assess for scoliosis progression in growing children. - Evaluate thyroid function: adjust levothyroxine if needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Somatropin may interact with certain medications and physiological conditions, requiring careful management.

Major Interactions (Avoid): - High‑dose glucocorticoids: may blunt growth‑promoting effects. - Insulin or oral hypoglycemics: increased risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: may need dose adjustment. - Antiepileptic drugs (e.g., phenobarbital, phenytoin): may reduce somatropin efficacy. - Estrogen therapy: can alter IGF‑1 response.